Introduction & Context
GLP-1 drugs exploded in popularity for diabetes and obesity management, with TikTok fueling off-label demand. Compounding pharmacies stepped in during shortages, operating under looser oversight.
Background & History
The FDA allows compounding when branded drugs are scarce, but manufacturers argue telehealth firms are skirting rules to boost margins. Lilly’s lawsuit follows Novo Nordisk’s similar actions in 2024.
Key Stakeholders & Perspectives
Patients seek affordable access; Lilly protects patent revenue; telehealth start-ups claim they’re filling a public-health gap; regulators balance safety with supply realities.
Analysis & Implications
Court rulings could redraw the telehealth-pharma map, potentially restricting online hormone and weight-loss clinics. Insurance formularies may tighten, pushing employers to renegotiate coverage.
Looking Ahead
Preliminary injunction hearings begin in June. Meanwhile, Senate health committees explore fast-tracking generic GLP-1 approvals to cool prices legally.